

DIASORIN RECEIVES THE FDA CLEARANCE ON THE COMMERCIALIZATION OF 1,25 VITAMIN D ON ITS LIAISON XL IN THE US MARKET

16 December 2014 - Saluggia (VC) - **DiaSorin** (FTSE Mid Cap: DIA) announces the FDA clearance of the **1,25 Dihydroxyvitamin D** in the US market. The fully automated test for the quantitative determination of Vitamin D levels in human serum samples is already available in Europe since June 2014.

John Walter, President of DiaSorin Inc., commented: *"The approval by the FDA of **1,25 Dihydroxyvitamin D** test strengthens our presence in the US market in the clinical area of bone metabolism where we are already a leader thanks to Vitamin D 25 OH. Additionally, the improved analytical sensitivity and precision of the cleared assay should allow better differential diagnosis in the management of chronic kidney disease for which the determination of Vitamin D 1, 25 is critical".*

Carlo Rosa, CEO of DiaSorin Group, commented: *"I am proud that DiaSorin is confirmed again the pioneer of the immunodiagnostics market, launching the first fully automated solution on our LIAISON XL for the determination of this important marker that represents one of the growth drivers of the DiaSorin of tomorrow".*

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	1,25 Dihydroxyvitamin D		
Diagnosis	Quantitative determination of 1,25 Dihydroxyvitamin D levels in human serum and plasma		
Business segment	Immunodiagnosics	✓	Molecular Diagnostics
Potential market	Between 10%-15% of the current Vitamin D 25 OH market		
Technology	CLIA	✓	Extraction
	ELISA		Amplification/Detection
	RIA		HLA Typing
Clinical Area	Infectious Disease		Infectious Disease
	Hepatitis and Retroviruses		
	Oncology & Endocrinology		Onco-hematology
	Bone & Mineral	✓	
	Cardiac Markers		
GI Stool Testing			

About DiaSorin

DiaSorin is an Italian multinational Group, worldwide leader in the field of In Vitro Diagnostics (IVD), and it is listed in the FTSE Italy Mid Cap Index. For over 40 years, the Group has been developing, manufacturing and selling worldwide test (blood test kits) for diagnosis of diseases in various clinical areas. Diasorin's offer is aimed at laboratories and hospital and is able to satisfy every type of requirement related to infectious diseases, cardiac markers, bone and metabolism, hepatitis and retrovirus, oncology and endocrinology. Diasorin offers to the market such a unique menu of immunodiagnostic tests in terms of width and specialty that it has earned the definition of "In Vitro Diagnostic Specialty". With the IVD market, DiaSorin is also focusing on offering products for molecular diagnostics.

For additional information, please contact:**Riccardo Fava**

Investor Relations and Corporate Communication Director

Tel: +39.0161.487988

riccardo.fava@diasorin.it**Margherita Sacerdoti**

Investor Relations Specialist

Tel: +39.0161.487456

margherita.sacerdoti@diasorin.it